« Back
Home /
Terazosin

Terazosin

Item no.	HY-B0371-10mM
Manufacturer	MedChem Express
CASRN	63590-64-7
Amount	10 mM
Category	Oncology Metabolism Diabetes Glucose Homeostasis Inhibitors & Compound Libraries Small Molecules By Organ Testicular & Prostate Cancer
Type	Inhibitors
Specific against	other
Purity	985.000
Citations	[1]Michel MC, et al. Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol. 1996 Feb;16(1):21-8.\|[2]Vincent J, et al. Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans. J Clin Invest. 1992 Nov;90(5):1763-8.\|[3]Ju M, et al. Efficacy of combination terazosin and nifedipine therapy in postoperative treatment of distal ureteral stones after transurethral ureteroscopic lithotripsy. J Int Med Res. 2020 Apr;48(4):300060520904851. Authorea. March 31, 2022. Eur J Med Chem. 2024 Mar 5:267:116209. Neurochem Int. 2021 Feb:143:104942. Research Square Preprint. 2022 Jul. Cell Prolif. 2025 Mar;58(3):e13764. Cell Rep Methods. 2023 Oct 23;3(10):100599. Res Sq. 2025 Mar 16.
Smiles	O=C(N1CCN(C2=NC(N)=C3C=C(OC)C(OC)=CC3=N2)CC1)C4OCCC4
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound1
Manufacturer - Applications	Metabolism-protein/nucleotide metabolism
Manufacturer - Category	Reference compound / Active compounds; API
Manufacturer - HS Code	H302-H315-H319-H335
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Product Description	Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment[1][2][3].
Manufacturer - Research Area	Metabolic Disease; Endocrinology; Cardiovascular Disease
Solubility	DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	GPCR/G Protein; Neuronal Signaling
Clinical information	Launched
Isoform	α adrenergic receptor
UNSPSC Code	12352005
Precautionary	P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362-P403+P233-P405-P501

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.